Cassiopea SpA’s (SKIN.SW) Winlevi, proposed for the treatment of acne, awaits the FDA decision on August 27, 2020.Winlevi (clascoterone cream 1%) is designed to work by targeting androgen receptors at the site of application, inhibiting the local (skin) effects of dihydrotestosterone (DHT), a key driver of acne lesion development.If approved, Winlevi will be the first new mechanism of action in the treatment of acne in nearly 40 years, offering dermatologists and patients a new and effective therapeutic alternative, according to the company.SKIN.SW closed Friday’s (Jul.24, 2020) trading at 39.50 CHF, down 0.25%.